Nanjing Delova's QP-6211 Achieves Primary Endpoints in Phase 3 Trials for Postoperative Pain Management
核心洞察
Nanjing Delova's QP-6211, a long-acting ropivacaine injection, achieved primary and all key secondary endpoints in two pivotal Phase 3 trials for postoperative pain (搜索) management following hemorrhoidectomy and bunionectomy surgeries.
The novel formulation demonstrated statistically significant reductions in postoperative pain (搜索) and opioid consumption through 72 hours compared to both placebo and standard ropivacaine hydrochloride injection.
QP-6211 utilizes Delova's proprietary Cryslova™ technology platform to provide continuous ropivacaine release for at least 5 days, positioning it as a potential best-in-class non-opioid option for postoperative pain (搜索).
Nanjing Delova Biotech Co., Ltd. (搜索) announced positive results from two pivotal Phase 3 clinical trials evaluating QP-6211, a long-acting ropivacaine injection, for postoperative pain (搜索) management following hemorrhoidectomy and bunionectomy surgeries. The investigational drug achieved primary and all key secondary endpoints in both placebo- and active-controlled trials, demonstrating statistically significant reductions in postoperative pain and opioid consumption through 72 hours.
Novel Extended-Release Formulation Shows Superior Pain Control
QP-6211 represents the first and only long-acting ropivacaine formulation with two positive Phase 3 datasets demonstrating superior and sustained postoperative pain (搜索) relief through the critical 72-hour postoperative period. The drug utilizes Delova's proprietary Cryslova™ technology platform, composed of a dilutable, aqueous (oil-free), injectable suspension containing ropivacaine.
Following administration, ropivacaine is released continuously and uniformly for at least 5 days, with consistent pharmacokinetic performance across different surgical models. This extended-release mechanism differentiates QP-6211 from standard ropivacaine formulations and positions it as a potential best-in-class non-opioid option for postoperative pain (搜索) management.
Phase 3 Trial Results in Hemorrhoidectomy Patients
The hemorrhoidectomy Phase 3 trial was a prospective, randomized, double-blind, placebo- and active-controlled, multicenter clinical trial involving 309 Chinese patients. The study evaluated the efficacy and safety of single-dose QP-6211 administered via infiltration for postoperative pain (搜索) control following hemorrhoidectomy surgery.
QP-6211 demonstrated statistically significant reductions in postoperative pain (搜索) and opioid consumption through 72 hours following infiltration compared to both ropivacaine hydrochloride injection and placebo. Results of other secondary endpoints in this Phase 3 trial were generally consistent with those of the primary endpoint.
Bunionectomy Trial Confirms Efficacy Profile
The bunionectomy Phase 3 trial followed a similar design, enrolling 185 Chinese patients in a prospective, randomized, double-blind, placebo- and active-controlled, multicenter study. Single-dose QP-6211 administered via infiltration for postoperative pain (搜索) control following bunionectomy surgery achieved the same positive outcomes as observed in the hemorrhoidectomy trial.
The drug showed statistically significant reductions in postoperative pain (搜索) and opioid consumption through 72 hours compared to both control groups. Secondary endpoint results were generally consistent with the primary endpoint findings.
Safety Profile and Tolerability
QP-6211 was generally well tolerated across both Phase 3 studies. The majority of adverse events were mild to moderate, and there were no serious adverse events related to QP-6211 treatment.
In the hemorrhoidectomy Phase 3 trial, the overall adverse event incidence in the QP-6211 group was similar to that in the placebo group. Adverse events reported in ≥5% of patients and more frequently than placebo included dyschezia (9.1% vs. 3.8%), fever (6.5% vs. 5.1%), constipation (5.8% vs. 3.8%), and diarrhea (5.2% vs. 1.3%).
The bunionectomy Phase 3 trial showed an even more favorable safety profile, with overall adverse event incidence lower in the QP-6211 group than in the placebo group, and no adverse events occurring in ≥5% of patients at a higher frequency than placebo.
Regulatory Submission and Commercial Potential
Based on these positive Phase 3 results, Nanjing Delova has submitted a New Drug Application for QP-6211 to China's National Medical Products Administration (NMPA). The company is a commercial-stage biotechnology company focused on developing novel non-opioid analgesics to address unmet medical needs globally.
Delova's first product, QP001 (meloxicam injection), is already approved for the management of moderate-to-severe pain in adults and is marketed as QAMZOVA® in the United States (FDA-approved) and 普坦宁® in China (NMPA-approved). The success of QP-6211 could further strengthen the company's position in the non-opioid pain management market.
Technology Platform and Mechanism of Action
QP-6211 is designed to provide prolonged postoperative local analgesia via infiltration, and potentially via peripheral nerve block or fascial plane block. Ropivacaine is an amide local anesthetic that differs from bupivacaine due to its high safety threshold for cardiotoxicity and greater selectivity for blocking A-delta and C pain fibers (搜索) relative to A-alpha motor fibers (搜索).
The Cryslova™ technology platform enables the extended-release characteristics that distinguish QP-6211 from conventional local anesthetics, potentially offering healthcare providers a more effective tool for managing postoperative pain (搜索) while reducing opioid dependence.